In Levaquin Patent Battle, Daiichi Scores Again

Law360, New York (March 20, 2006, 12:00 AM EST) -- In its second big win in a high-stakes patent battle over the anti-infective drug Levaquin, Japanese drug maker Daiichi Pharmaceutical Co. has been granted summary judgment on its motion for no inequitable conduct, effectively tossing a bid by four generic challengers to duplicate the blockbuster drug.

The suit, brought by Daiichi, Johnson & Johnson, and Ortho-Mcneil Pharmaceutical Inc., has been ongoing in the U.S. District Court in New Jersey since June 2002.

The case stemmed from Abbreviated New Drug Application (ANDA) filings made by Teva Pharmaceuticals...
To view the full article, register now.